Evidence map›Paper›PMID 30065769›Full record

ArticleResearch in pharmaceutical sciences2018

Structure based design and anti-breast cancer evaluation of some novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor inhibitors.

Zahra Haghighijoo, Zahra Rezaei, Mansooreh Jaberipoor, Samaneh Taheri, Meysam Jani, Soghra Khabnadideh

Open access · goldAbstract read
In one paragraph

Article in Research in pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zahra HaghighijooPharmaceutical Sciences Research Center, Pharmacy School, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.
Zahra RezaeiPharmaceutical Sciences Research Center, Pharmacy School, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.
Mansooreh JaberipoorShiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.
Samaneh TaheriPharmaceutical Sciences Research Center, Pharmacy School, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.
Meysam JaniPharmaceutical Sciences Research Center, Pharmacy School, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.
Soghra KhabnadidehPharmaceutical Sciences Research Center, Pharmacy School, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quinazoline is one of the most widespread scaffolds amongst natural and synthetic bioactive compounds. Recently the quinazoline derivatives and in particular the 4-anilinoquinazolines have attracted much attention for their anticancer properties due to their capability to stabilize the kinase activity of epidermal growth factor receptor (EGFR). A series of fifteen previously designed and synthesized 4-anilinoquinazoline analogs

Indexed as

4-AnilinoquinazolineCytotoxic activityDockingEGFR

Identifiers

PMID30065769
PMCPMC6040169
OpenAlexW2810073833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.